Journal: Cancer Medicine

Article Title: Upregulated IQUB promotes cell proliferation and migration via activating Akt/ GSK 3β/β‐catenin signaling pathway in breast cancer

doi: 10.1002/cam4.1568

Figure Lengend Snippet: IQUB is significantly upregulated in human breast cancer tissues and cells. A, IQUB protein expression (the brown staining areas) was increased in breast cancer, which was detected in 110 cases of human breast cancer tissue microarray by immunohistochemistry. B, The expression of IQUB in poor differentiation of breast cancer tissues was higher than that in well differentiation of breast cancer tissues. C, IQUB mRNA expression was upregulated in breast cancer tissues (16/20) than paired normal breast tissues which was analyzed by RT ‐ qPCR ( x ‐axis represent 20 pairs of tissue samples). D, IQUB mRNA and protein expression were detected by RT ‐ qPCR and Western blotting in normal breast cell line MCF ‐10A and breast cancer cell lines MCF ‐7 and MDA ‐ MB ‐231. Values represent the mean ± SD from 3 independent measurements. ** P < .01, *** P < .001

Article Snippet: The human breast cancer tissue microarray (the TMA ID: BC081120a) was purchased from Alenabio company (Xi'an, China) which contains 110 cases of breast cancer tissues and corresponding paracancerous tissues.

Techniques: Expressing, Staining, Microarray, Immunohistochemistry, Quantitative RT-PCR, Western Blot

Journal: Frontiers in Immunology

Article Title: TGF-β and TNF-α interaction promotes the expression of MMP-9 through H3K36 dimethylation: implications in breast cancer metastasis

doi: 10.3389/fimmu.2024.1430187

Figure Lengend Snippet: MMP-9 expression is associated with TGF-β and TNF-α in breast cancer tissues. Immunohistochemical staining was done for MMP-9, TGF-β, and TNF-α expressions. Tissue microarray TMA slides (88 breast cancer tissues from breast cancer patients) were subjected to immunohistochemistry using antibodies against MMP-9, TGF-β, and TNF-α. Based on IHC staining intensities of TGF-β and TNF-α, patients’ samples were divided into four groups (Low TNF-α- Low TGF-β; Low TNF-α- High TGF-β; High TNF-α- Low TGF-β; High TNF-α- High TGF-β. (A) Scatter Plot Graph for TNF-α and TGF-β. (B) Scatter Plot Graph for TNF-α and TGF-β with indication of patients with primary cancer, metastasis and normal breast cancer tissues. (C) MMP-9 expression was elevated in the breast cancer tissues (n=24 patients) having high levels of TGF-β and TNF-α compared to the tissues (n=20 patients) having less TGF-β and TNF-α. (D) Representative IHC images of the samples of breast cancer tissues with low levels of MMP-9, TGF-β and TNF-α. (E) Representative IHC images of the samples of breast cancer tissues showing high levels of MMP-9, TGF-β and TNF-α. All data is presented as the mean ± SD. *p < 0.05.

Article Snippet: Ethical approval was not required for the studies involving humans because We purchased commercial breast cancer tissue microarray (TMA) from US Biomax Inc.(BRM961a) https://www.tissuearray.com/tissue-arrays/Breast/BRM961b ; TissueArray.Com LLC 1(5885 Crabbs Branch Way, Derwood, MD 20855, USA.

Techniques: Expressing, Immunohistochemical staining, Staining, Microarray, Immunohistochemistry

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

doi: 10.1158/1078-0432.CCR-18-2523

Figure Lengend Snippet: (A) Baseline expression of selected DDR markers was demonstrated and quantified in a colorectal tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue microarray cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.

Article Snippet: Baseline biological variability was established for each biomarker across 64 individual cores from 32 colorectal (CRC) tumor resections contained in a paraffin-embedded colorectal tissue microarray (TMA; Indivumed, Hamburg, Germany).

Techniques: Expressing, Microarray, Marker, Quantitation Assay, Derivative Assay

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

doi: 10.1158/1078-0432.CCR-18-2523

Figure Lengend Snippet: Representative H&E and immunofluorescence (IFA) images from 3 patients with advanced colorectal cancer enrolled in NCI trial NCT01851369 before and 5 days after start of treatment with a DNA damaging therapeutic regimen consisting of TCR102 plus temozolomide administered orally once daily. Red scale bar represents 10 μm.

Article Snippet: Baseline biological variability was established for each biomarker across 64 individual cores from 32 colorectal (CRC) tumor resections contained in a paraffin-embedded colorectal tissue microarray (TMA; Indivumed, Hamburg, Germany).

Techniques: Immunofluorescence